28729154Maio M, Scherpereel A, CalabrĂ² L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HLThe Lancet. OncologyAntibodies, Monoclonal; Antineoplastic Agents; Lung Neoplasms; MesotheliomaAged; Antibodies, Monoclonal, Humanized; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Mesothelioma, Malignant; Middle Aged; Response Evaluation Criteria in Solid Tumors; Survival Rate; Treatment OutcomeTremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017 09; 18(9):1261-1273.Lancet Oncol2017-07-17T00:00:002017Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.prns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000368Living Beings1341183530.294764AgedD000970Chemicals & Drugs40723510.435461Antineoplastic AgentsD000911Chemicals & Drugs33713760.622749Antibodies, MonoclonalD004311Procedures33818220.708936Double-Blind MethodAuthorship 111444170.1571620.1571621authors10.2515has subject areaD008654Disorders573090.774622MesotheliomaD008875Concepts & IdeasLiving Beings1473249570.258811Middle AgedD008175Disorders32822600.404525Lung NeoplasmsD005260Physiology1992444050.191167FemaleD006801Living Beings2262862810.130052HumansD008297Physiology1931408600.201617MaleMedicine-Hematology and OncologyD016896Concepts & Ideas101179490.402389Treatment OutcomeD061067Chemicals & Drugs2139290.656166Antibodies, Monoclonal, HumanizedD015996Concepts & Ideas45518560.724887Survival RateD066066Concepts & Ideas36560.974296Response Evaluation Criteria in Solid TumorsD018572Concepts & Ideas25812030.792696Disease-Free SurvivalUniversity of ChicagoHedyKindler32lgBaUZHP75hHlsaUXv9Gq0+s+oHedy Kindler41.78927490000000-87.601250000000002499Kindler, HedyProfessortrue1ProfessorProfessor